Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Astellas PharmaALPMF -7.00%73 Graham Number is $5.72 as of Mar. 2026, which is 104% above its 10-year median of 2.81. GuruFocus rates ALPMF with a GF Score™ of 73/100 and a GF Value™ of $14.19 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 604 Drug Manufacturers companies, Astellas Pharma ranks worse than 69.87% on this metric.
Graham Number is a figure that measures a stock's fundamental value by taking into account the company's earnings per share and book value per share. The Graham number is the upper bound of the price range that a defensive investor should pay for the stock. According to the theory, any stock price below the Graham number is considered undervalued, and thus worth investing in.
As of today (2026-07-15), the stock price of Astellas Pharma is $11.95. Astellas Pharma's graham number for the quarter that ended in Mar. 2026 was $5.72. Therefore, Astellas Pharma's Price to Graham Number ratio for today is 2.09.
The historical rank and industry rank for Astellas Pharma's Graham Number or its related term are showing as below:
ALPMF'
s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.63 Med: 2.81 Max: 3.13
Current: 2.25
During the past 13 years, the highest Price to Graham Number ratio of Astellas Pharma was 3.13. The lowest was 1.63. And the median was 2.81.
ALPMF's Price-to-Graham-Number is ranked worse than 69.87% of 604
companies
in the Drug Manufacturers industry
Industry Median: 1.56
vs ALPMF: 2.25
Graham Number is a combination of asset valuation and earnings power valuation. It is a very conservative way of valuing a stock.
Astellas Pharma (OTCPK:ALPMF) Graham Number Explanation
Ben Graham actually did not publish a formula like this. But he wrote in The Intelligent Investor (1948 version) regarding to the criteria for purchases:
Current price should not be more than 15 times average earnings of the past three years.
Current price should not be more than 1.5 times the book value last reported. However, a multiplier of earnings below 15 could justify a correspondingly higher multiplier of assets. As a rule of thumb we suggest that the product of the multiplier times the ratio of price to book value should not exceed 22.5. (This figure corresponds to 15 times earnings and 1.5 times book value. It would admit an issue selling at only 9 times earnings and 2.5 times asset value, etc.)
Unlike valuation methods such as DCF or Discounted Earnings, the Graham number does not take growth into the valuation. Unlike the valuation methods based on book value alone, it takes into account the earnings power. Therefore, the Graham Number is a combination of asset valuation and earnings power valuation.
In general, the Graham number is a very conservative way of valuing a stock. It cannot be applied to companies with negative book values.
Astellas Pharma's Price to Graham number Ratio for today is calculated as
Price to Graham number
=
Share Price (Today)
/
Graham number (Q: Mar. 2026 )
=
11.95
/
5.72
=
2.09
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Please keep these in mind:
1. Graham Number does not take growth into account. Therefore it underestimates the values of the companies that have good earnings growth. We feel that if the earnings per share grows more than 10% a year, Graham Number underestimates the value.
2. Graham Number punishes the companies that have temporarily low earnings. Therefore, an average of earnings makes more sense in the calculation of Graham Number.
3. Graham Numbers underestimates companies that are light with book.
Astellas Pharma Graham Number Related Terms
Astellas Pharma Graham Number Historical Data
* Premium members only.
The historical data trend for Astellas Pharma's Graham Number can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Astellas Pharma's Price-to-Graham-Number, along with its competitors' market caps and Price-to-Graham-Number data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Astellas Pharma Price-to-Graham-Number vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Astellas Pharma's Price-to-Graham-Number distribution charts can be found below:
* The bar in red indicates where Astellas Pharma's Price-to-Graham-Number falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Astellas Pharma (ALPMF) has a Graham Number of $5.72 as of Mar. 2026. The Graham Number values a company based on its per-share earnings and book value. View historical data on Astellas Pharma and its competitors. This is 104% above median its historical median of 2.81. Over the past decade, Astellas Pharma's Graham Number has ranged from 1.63 to 3.13. According to the industry distribution chart, Astellas Pharma ranks #422 out of 604 companies in the Drug Manufacturers industry, placing it in the top 69.9%.
Is Astellas Pharma's Graham Number too high?
Astellas Pharma's current Graham Number of $5.72 is 104% above median its 10-year median of 2.81. Over the past 10 years, this metric has ranged from a low of 1.63 to a high of 3.13. The Drug Manufacturers industry median Graham Number is 1.56. Astellas Pharma's value of $5.72 is 266.7% above this industry median. Based on the distribution chart, Astellas Pharma ranks #422 out of 604 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Astellas Pharma has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Astellas Pharma's Graham Number compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Astellas Pharma ranks #422 out of 604 companies for Graham Number. This places Astellas Pharma in the lower half of its industry. The industry median Graham Number is 1.56. Astellas Pharma's value of $5.72 is 266.7% above this benchmark. Historically, Astellas Pharma's own Graham Number has ranged from 1.63 to 3.13 over the past decade. While the company's 10-year median is 2.81 vs. the industry median of 1.56, Astellas Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Graham Number for a Drug Manufacturers company?
The median Graham Number among Drug Manufacturers companies is 1.56, based on 604 companies in the industry. Companies in the top quartile (top 25%) have a Graham Number significantly above this median, while those in the bottom quartile fall well below. However, Graham Number should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Astellas Pharma's current Graham Number of $5.72 is 266.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Graham Number mean?
A high Graham Number can signal that a stock is expensive relative to its fundamentals. The Graham Number values a company based on its per-share earnings and book value. View historical data on Astellas Pharma and its competitors. For the Drug Manufacturers industry, the median Graham Number is 1.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Astellas Pharma's current Graham Number is $5.72, which is 104% above median its own 10-year median of 2.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astellas Pharma stock overvalued right now?
Based on GuruFocus' analysis, Astellas Pharma (ALPMF) is currently considered Modestly Undervalued. The stock's GF Value™ is $14.19, compared to a current price of $11.95 — trading 15.8% below its estimated fair value. The current Graham Number is $5.72, which is 104% above median its 10-year median of 2.81 and 266.7% above the Drug Manufacturers industry median of 1.56. Astellas Pharma's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Graham Number calculated?
Graham Number is calculated from a company's financial statements. For Astellas Pharma (ALPMF), the current Graham Number is $5.72 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Astellas Pharma (ALPMF) Overvalued in 2026?
Based on GuruFocus' analysis, Astellas Pharma stock appears to be undervalued.
The current stock price of $11.95 is trading 15.8% below its estimated GF Value™ of $14.19.
GuruFocus considers Astellas Pharma to be Modestly Undervalued.
Key valuation signals for ALPMF:
Graham Number: $5.72 (104% above median its 10-year median of 2.81)
GF Value™: $14.19 vs. price of $11.95 (15.8% below fair value)
Industry Position: 266.7% above the Drug Manufacturers median (#422 of 604)
No single metric tells the full story. See the ALPMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Astellas Pharma Inc is a specialty international pharmaceutical company. The company focuses on accelerating the discovery, development, and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.
73GF Score
Get the complete analysis for ALPMF
Graham Number is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALPMF has been successfully added to your 
